{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:38:10Z","timestamp":1777495090333,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Cannonball Kids cancer, Sid Strong Foundation, Elaine Roberts Foundation, Open Hands Overflowing Hearts, and Starr Fund-Vince Lombardi Cancer Foundation."},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA229102"],"award-info":[{"award-number":["T32 CA229102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA091078"],"award-info":[{"award-number":["T32 CA091078"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA183926"],"award-info":[{"award-number":["T32 CA183926"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA229102"],"award-info":[{"award-number":["T32 CA229102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004143","name":"Society of University Surgeons Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004143","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5T32GM008361"],"award-info":[{"award-number":["5T32GM008361"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA013148"],"award-info":[{"award-number":["CA013148"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41417-021-00334-4","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T08:07:26Z","timestamp":1618560446000},"page":"558-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CRISPR\/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-3927","authenticated-orcid":false,"given":"Raoud","family":"Marayati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Stafman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura V.","family":"Bownes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-3948","authenticated-orcid":false,"given":"Colin H.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-5614","authenticated-orcid":false,"given":"Hooper R.","family":"Markert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet L.","family":"Easlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-169X","authenticated-orcid":false,"given":"David K.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Mroczek-Musulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-0527","authenticated-orcid":false,"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"334_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40880-019-0411-7","volume":"39","author":"J Feng","year":"2019","unstructured":"Feng J, Polychronidis G, Heger U, Frongia G, Mehrabi A, Hoffmann K. Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond). 2019;39:62.","journal-title":"Cancer Commun (Lond)"},{"key":"334_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15430\/JCP.2018.23.3.109","volume":"23","author":"X Zhang","year":"2018","unstructured":"Zhang X, Song M, Kundu JK, Lee MH, Liu ZZ. PIM kinase as an executional target in cancer. J Cancer Prev. 2018;23:109\u201316.","journal-title":"J Cancer Prev"},{"key":"334_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/med.21284","volume":"34","author":"M Narlik-Grassow","year":"2014","unstructured":"Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine\/threonine kinases in cancer. Med Res Rev. 2014;34:136\u201359.","journal-title":"Med Res Rev"},{"key":"334_CR4","doi-asserted-by":"publisher","first-page":"22665","DOI":"10.18632\/oncotarget.25205","volume":"9","author":"LL Stafman","year":"2018","unstructured":"Stafman LL, Mruthyunjayappa S, Waters AM, Garner EF, Aye JM, Stewart JE, et al. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget. 2018;9:22665\u201379.","journal-title":"Oncotarget"},{"key":"334_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1349-7006.2007.00390.x","volume":"98","author":"BK Popivanova","year":"2007","unstructured":"Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto-oncogene, Pim-3 with serine\/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci. 2007;98:321\u20138.","journal-title":"Cancer Sci"},{"key":"334_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130340","volume":"10","author":"NM Santio","year":"2015","unstructured":"Santio NM, Eerola SK, Paatero I, Yli-Kauhaluoma J, Anizon F, Moreau P, et al. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts. PLoS One. 2015;10:e0130340.","journal-title":"PLoS One"},{"key":"334_CR7","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","volume":"68","author":"D Morishita","year":"2008","unstructured":"Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68:5076\u201385.","journal-title":"Cancer Res"},{"key":"334_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tranon.2018.10.008","volume":"12","author":"LL Stafman","year":"2019","unstructured":"Stafman LL, Williams AP, Garner EF, Aye JM, Stewart JE, Yoon KJ, et al. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma. Transl Oncol. 2019;12:200\u20138.","journal-title":"Transl Oncol"},{"key":"334_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jpedsurg.2019.02.029","volume":"54","author":"LL Stafman","year":"2019","unstructured":"Stafman LL, Waldrop MG, Williams AP, Aye JM, Stewart JE, Mroczek-Musulman E, et al. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival. J Pediatr Surg. 2019;54:1206\u201313.","journal-title":"J Pediatr Surg"},{"key":"334_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-2-39","volume":"2","author":"S Mocellin","year":"2004","unstructured":"Mocellin S, Provenzano M. RNA interference: learning gene knock-down from cell physiology. J Transl Med. 2004;2:39.","journal-title":"J Transl Med"},{"key":"334_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262\u201378.","journal-title":"Cell"},{"key":"334_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1593\/tlo.12505","volume":"6","author":"LA Gillory","year":"2013","unstructured":"Gillory LA, Stewart JE, Megison ML, Nabers HC, Mroczek-Musulman E, Beierle EA. FAK inhibition decreases hepatoblastoma survival both in vitro and in vivo. Transl Oncol. 2013;6:206\u201315.","journal-title":"Transl Oncol"},{"key":"334_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"334_CR14","doi-asserted-by":"crossref","unstructured":"Stephenson FH, ScienceDirect. Calculations for molecular biology and biotechnology: a guide to mathematics in the laboratory, Chapter 3 - Cell Growth: Academic Press; 2010.","DOI":"10.1016\/B978-0-12-375690-9.00003-6"},{"key":"334_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"334_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562\u201378.","journal-title":"Nat Protoc"},{"key":"334_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511\u20135.","journal-title":"Nat Biotechnol"},{"key":"334_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"334_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000324","volume":"5","author":"F Cheng","year":"2009","unstructured":"Cheng F, Weidner-Glunde M, Varjosalo M, Rainio EM, Lehtonen A, Schulz TF, et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog. 2009;5:e1000324.","journal-title":"PLoS Pathog"},{"key":"334_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70\u20138.","journal-title":"J Immunol Methods"},{"key":"334_CR21","first-page":"365","volume":"132","author":"S Rozen","year":"2000","unstructured":"Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365\u201386.","journal-title":"Methods Mol Biol"},{"key":"334_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/abio.1999.4085","volume":"270","author":"J Winer","year":"1999","unstructured":"Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41\u20139.","journal-title":"Anal Biochem"},{"key":"334_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0344-0338(11)80557-1","volume":"191","author":"D Graham","year":"1995","unstructured":"Graham D, Magee H, Kierce B, Ball R, Dervan P, O\u2019Meara A. Evaluation of Ki-67 reactivity in neuroblastoma using paraffin embedded tissue. Pathol Res Pr. 1995;191:87\u201391.","journal-title":"Pathol Res Pr"},{"key":"334_CR24","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers12071765","volume":"12","author":"D Aldinucci","year":"2020","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 axis in cancer progression. Cancers (Basel). 2020;12:1765.","journal-title":"Cancers (Basel)"},{"key":"334_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gad.7.5.812","volume":"7","author":"V Baldin","year":"1993","unstructured":"Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812\u201321.","journal-title":"Genes Dev"},{"key":"334_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.onc.1203355","volume":"19","author":"A Eichmann","year":"2000","unstructured":"Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene. 2000;19:1215\u201324.","journal-title":"Oncogene"},{"key":"334_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-011-0097-2","volume":"15","author":"B Yan","year":"2012","unstructured":"Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, et al. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer. 2012;15:188\u201397.","journal-title":"Gastric Cancer"},{"key":"334_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1593\/neo.13172","volume":"15","author":"U Weirauch","year":"2013","unstructured":"Weirauch U, Beckmann N, Thomas M, Grunweller A, Huber K, Bracher F, et al. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia. 2013;15:783\u201394.","journal-title":"Neoplasia"},{"key":"334_CR29","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2015-11-685032","volume":"127","author":"M Bellon","year":"2016","unstructured":"Bellon M, Lu L, Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood. 2016;127:2439\u201350.","journal-title":"Blood"},{"key":"334_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/10428190310001641251","volume":"45","author":"AM Cohen","year":"2004","unstructured":"Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45:951\u20135.","journal-title":"Leuk Lymphoma"},{"key":"334_CR31","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1158\/0008-5472.CAN-05-4272","volume":"66","author":"YY Li","year":"2006","unstructured":"Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine\/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 2006;66:6741\u20137.","journal-title":"Cancer Res"},{"key":"334_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ijc.20719","volume":"114","author":"C Fujii","year":"2005","unstructured":"Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, et al. Aberrant expression of serine\/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer. 2005;114:209\u201318.","journal-title":"Int J Cancer"},{"key":"334_CR33","first-page":"9392","volume":"20","author":"YY Li","year":"2014","unstructured":"Li YY, Mukaida N. Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol. 2014;20:9392\u2013404.","journal-title":"World J Gastroenterol"},{"key":"334_CR34","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","volume":"24","author":"H Mikkers","year":"2004","unstructured":"Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004;24:6104\u201315.","journal-title":"Mol Cell Biol"},{"key":"334_CR35","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1002\/j.1460-2075.1995.tb07251.x","volume":"14","author":"NM van der Lugt","year":"1995","unstructured":"van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J. 1995;14:2536\u201344.","journal-title":"EMBO J"},{"key":"334_CR36","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.12659\/MSM.898223","volume":"22","author":"Y Qu","year":"2016","unstructured":"Qu Y, Zhang C, Du E, Wang A, Yang Y, Guo J, et al. Pim-3 is a critical risk factor in development and prognosis of prostate cancer. Med Sci Monit. 2016;22:4254\u201360.","journal-title":"Med Sci Monit"},{"key":"334_CR37","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.7314\/APJCP.2015.16.8.3325","volume":"16","author":"H Zhuang","year":"2015","unstructured":"Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L, Du X, et al. Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16:3325\u201331.","journal-title":"Asian Pac J Cancer Prev"},{"key":"334_CR38","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3892\/or.2014.3158","volume":"31","author":"B Liu","year":"2014","unstructured":"Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY. Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Oncol Rep. 2014;31:2625\u201334.","journal-title":"Oncol Rep"},{"key":"334_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibs.2019.09.007","volume":"45","author":"AE Leroux","year":"2020","unstructured":"Leroux AE, Biondi RM. Renaissance of allostery to disrupt protein kinase interactions. Trends Biochem Sci. 2020;45:27\u201341.","journal-title":"Trends Biochem Sci"},{"key":"334_CR40","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/leu.2016.379","volume":"31","author":"JR Nair","year":"2017","unstructured":"Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, et al. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia. 2017;31:1715\u201326.","journal-title":"Leukemia"},{"key":"334_CR41","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/carcin\/bgs176","volume":"33","author":"M Narlik-Grassow","year":"2012","unstructured":"Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Peregrina S, Garcia-Serelde B, Munoz-Galvan S, et al. The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis. 2012;33:1479\u201386.","journal-title":"Carcinogenesis"},{"key":"334_CR42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-13-2062","volume":"20","author":"PD Garcia","year":"2014","unstructured":"Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014;20:1834\u201345.","journal-title":"Clin Cancer Res"},{"key":"334_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1240-0","volume":"18","author":"JJ Sharpe","year":"2017","unstructured":"Sharpe JJ, Cooper TA. Unexpected consequences: exon skipping caused by CRISPR-generated mutations. Genome Biol. 2017;18:109.","journal-title":"Genome Biol"},{"key":"334_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2019.0064","volume":"3","author":"G Joberty","year":"2020","unstructured":"Joberty G, Falth-Savitski M, Paulmann M, Bosche M, Doce C, Cheng AT, et al. A tandem guide RNA-based strategy for efficient CRISPR gene editing of cell populations with low heterogeneity of edited alleles. CRISPR J. 2020;3:123\u201334.","journal-title":"CRISPR J"},{"key":"334_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4:e264.","journal-title":"Mol Ther Nucleic Acids"},{"key":"334_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.celrep.2015.06.049","volume":"12","author":"H Ma","year":"2015","unstructured":"Ma H, Dang Y, Wu Y, Jia G, Anaya E, Zhang J, et al. A CRISPR-based screen identifies genes essential for west-nile-virus-induced cell death. Cell Rep. 2015;12:673\u201383.","journal-title":"Cell Rep"},{"key":"334_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.canep.2013.03.004","volume":"37","author":"JE Heck","year":"2013","unstructured":"Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, et al. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol. 2013;37:390\u20135.","journal-title":"Cancer Epidemiol"},{"key":"334_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/01926230290105802","volume":"30","author":"VS Turusov","year":"2002","unstructured":"Turusov VS, Torii M, Sills RC, Willson GA, Herbert RA, Hailey JR, et al. Hepatoblastomas in mice in the US National Toxicology Program (NTP) studies. Toxicol Pathol. 2002;30:580\u201391.","journal-title":"Toxicol Pathol"},{"key":"334_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00383-009-2349-3","volume":"25","author":"JD Horton","year":"2009","unstructured":"Horton JD, Lee S, Brown SR, Bader J, Meier DE. Survival trends in children with hepatoblastoma. Pediatr Surg Int. 2009;25:407\u201312.","journal-title":"Pediatr Surg Int"},{"key":"334_CR50","doi-asserted-by":"publisher","first-page":"21978","DOI":"10.18632\/oncotarget.25140","volume":"9","author":"B Mertens","year":"2018","unstructured":"Mertens B, Cristina de Araujo Nogueira T, Topalis D, Stranska R, Snoeck R, Andrei G. Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice. Oncotarget. 2018;9:21978\u20132000.","journal-title":"Oncotarget"},{"key":"334_CR51","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/onc.2009.504","volume":"29","author":"Y Wu","year":"2010","unstructured":"Wu Y, Wang YY, Nakamoto Y, Li YY, Baba T, Kaneko S, et al. Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene. 2010;29:2228\u201337.","journal-title":"Oncogene"},{"key":"334_CR52","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/MD.0000000000004766","volume":"95","author":"JC Chang","year":"2016","unstructured":"Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltim). 2016;95:S20\u20135.","journal-title":"Medicine (Baltim)"},{"key":"334_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1385\/MN:34:3:153","volume":"34","author":"JB Jensen","year":"2006","unstructured":"Jensen JB, Parmar M. Strengths and limitations of the neurosphere culture system. Mol Neurobiol. 2006;34:153\u201361.","journal-title":"Mol Neurobiol"},{"key":"334_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.10.003","volume":"51","author":"ES Villodre","year":"2016","unstructured":"Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016;51:1\u20139.","journal-title":"Cancer Treat Rev"},{"key":"334_CR55","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/ijc.28690","volume":"135","author":"LE Iv Santaliz-Ruiz","year":"2014","unstructured":"Iv Santaliz-Ruiz LE, Xie X, Old M, Teknos TN, Pan Q. Emerging role of nanog in tumorigenesis and cancer stem cells. Int J Cancer. 2014;135:2741\u20138.","journal-title":"Int J Cancer"},{"key":"334_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jmcb\/mjy080","volume":"12","author":"MA Mamun","year":"2020","unstructured":"Mamun MA, Mannoor K, Cao J, Qadri F, Song X. SOX2 in cancer stemness: tumor malignancy and therapeutic potentials. J Mol Cell Biol. 2020;12:85\u201398.","journal-title":"J Mol Cell Biol"},{"key":"334_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/cas.12691","volume":"106","author":"J Neradil","year":"2015","unstructured":"Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015;106:803\u201311.","journal-title":"Cancer Sci"},{"key":"334_CR58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.trsl.2014.07.009","volume":"165","author":"AA Bahnassy","year":"2015","unstructured":"Bahnassy AA, Fawzy M, El-Wakil M, Zekri AR, Abdel-Sayed A, Sheta M. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res. 2015;165:396\u2013406.","journal-title":"Transl Res"},{"key":"334_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fped.2016.00022","volume":"4","author":"RR Rikhi","year":"2016","unstructured":"Rikhi RR, Spady KK, Hoffman RI, Bateman MS, Bateman M, Howard LE. Hepatoblastoma: a need for cell lines and tissue banks to develop targeted drug therapies. Front Pediatr. 2016;4:22.","journal-title":"Front Pediatr"},{"key":"334_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.gene.2012.12.106","volume":"518","author":"S Costantini","year":"2013","unstructured":"Costantini S, Di Bernardo G, Cammarota M, Castello G, Colonna G. Gene expression signature of human HepG2 cell line. Gene. 2013;518:335\u201345.","journal-title":"Gene"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00334-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T23:04:06Z","timestamp":1652828646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-021-00334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1038\/s41417-021-00334-4","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}